Here is a link I found helpful from the International Myeloma Foundation (IMF), referencing six different research studies that are still accepting multiple myeloma patients:  Carfilzomib Treatment Studies.  As you may recall, there was a lot of excitement about carfilzomib’s potential to reduce some of the side effects associated with a similar drug, Velcade, at last Decembers ASH conference in New Orleans. Keep in mind, Velcade is already FDA approved for use in newly diagnosed as well as multiple myeloma patients who have relapsed.  But early studies have shown Carfilzomib to be effective for some refractory (relapsed and drug resistant) myeloma patients. 

Feel good and keep smiling!  Pat